Drug Approval | March 19, 2024
Sun Pharmaceuticals receives approval for Winlevi in Australia
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
WINLEVI works differently from any other topical acne treatment
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
European operations' revenue grew 58.4% to Rs 599.7 crore
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)